Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 6/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | TGM2 | P21980 | 2/20 | 0.47 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | BRD1 | O95696 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988608 | 0.89 | EPHB4 (0.47) | BTKKDM4EPGRTGM2LMNA | |
| SCHEMBL23988609 | 0.88 | BTK (0.47) | BTKCYP19A1KDM4ETGM2SMN1; SMN2 | |
| SCHEMBL23988634 | 0.87 | TGM2 (0.58) | KDM4EPGRTGM2TRIM24BRD1 | |
| SCHEMBL9568733 | 0.86 | BTK (0.63) | BTKKDM4ETGM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL9568677 | 0.84 | TGM2 (0.58) | BTKTGM2ALDH1A1PKM | |
| SCHEMBL20885070 | 0.84 | LMNA (0.56) | BTKKDM4ETGM2SMN1; SMN2ALDH1A1 | |
| SCHEMBL23988607 | 0.81 | PGR (0.54) | BTKPGRTGM2ALDH1A1MAPT | |
| SCHEMBL17660300 | 0.79 | EPHB4 (0.61) | BTKTGM2FYNSRC | |
| SCHEMBL20885056 | 0.78 | TGM2 (0.63) | KDM4ETGM2ALDH1A1LMNAMAPT | |
| SCHEMBL7175064 | 0.78 | HSD17B2 (0.67) | CYP19A1KDM4EPGRTRIM24BRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155556-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods for treating PI3K-mediated disorders | PI4KA, PIK3CA, PI4KB | BTK 58/4885CYP19A1 2168/4885KDM4E 2713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.